Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Saturday, October 28, 2023Santhera Pharmaceuticals announces that the US Food and Drug Administration has approved AGAMREE oral suspension mgml for the treatment of Duchenne muscular dystrophy in patients years of age and older
Mustang Bio's IND Application for MB-109, a Novel Combination Therapy for Recurrent Glioblastoma and High-Grade Astrocytoma, Accepted by FDA
Friday, October 27, 2023Mustang Bio Inc a clinicalstage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for difficulttotreat cancers and rare genetic diseases
Reliable Vial Blinding From Schreiner Medipharm for International Clinical Trial
Friday, October 27, 2023Schreiner MediPharm has developed a reliable blinding solution for vials used for clinical dosing The selfadhesive film labels are colored as well as semitransparent As a result the different liquids of the investigational drug
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Friday, October 27, 2023CanFite BioPharma Ltd a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases today announced that it entered into an agreement
Biogen's Tau-Targeting ASO Shows Promise for Early Alzheimer's Treatment
Thursday, October 26, 2023Biogen Inc reported new Phase b clinical data from the study of BIIB an investigational antisense oligonucleotide therapy targeting tau in mild Alzheimers disease The data showed favorable trends on multiple exploratory endpoints of cognition
EFFECTOR Therapeutics and Northwestern University Collaborate on AML Trial with Tomivosertib
Wednesday, October 25, 2023EFFECTOR Therapeutics Inc NASDAQ EFTR a leader in the development of selective translation regulator inhibitors STRIs for the treatment of cancer today announced the initiation of dosing in an investigatorinitiated Phase dose
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
Wednesday, October 25, 2023Immatics NV NASDAQ IMTX Immatics a clinicalstage biopharmaceutical company active in the discovery and development of T cellredirecting cancer immunotherapies today announced that its IMA TCRT program
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Wednesday, October 25, 2023Araclon Biotech a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases today announced encouraging final results from its Phase trial
Cybin Completes Acquisition of Small Pharma Inc. To Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
Tuesday, October 24, 2023Cybin Inc and Small Pharma Inc are pleased to announce the completion of the previouslyannounced acquisition by Cybin of Small Pharma
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
Tuesday, October 24, 2023Alzamend Neuro Inc a clinicalstage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease bipolar disorder major depressive disorder and posttraumatic stress disorder
